Ann: Chimeric to present at Biotech Showcase at JPM week, page-12

See below ann. of first dosing for Gracell’ phase 1b/2 only 3 months ago and already taken over


All the slides in Chimeric’s presentations are showing investors the value infliction points and we amongst the deal making territory


Jenn has highlighted to us that this is where things get interesting

I agree with previous posters with a limited expectation of a deal right after this conference but these are the activities one needs to participate in to get not only a deal but what investors would like in the best deal possible

i was impressed with Gracell’s team and especially their CEO and I believe founder


then their tech worked

I see similarities in CHM hence why invested here

I’m personally hoping to develop more of the portfolio and especially highlight the nk platform potential and follow the trials of the car drugs enhanced with the platform


CHM potentially with a NK platform enhancing novel Chloroxtin and CDH17 targeted treatments


the team is in place and they have great track records amd the tech is showing signs of working well

I don’t need to see much more then that…


simple investment thesis that hopefully pays off

look at RAC when at $0.045 then up to over $4…that was a fun ride


(not saying chm to $4 as more shares outstanding here)

i like our team and tech so much more here at CHM and the I believe the potential value doesn’t compare

locked and loaded